Last 12 months
Inside the activity.
0 purchase rows · 106 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 19 |
| Dec 2025 | 0 | 4 |
| Jan 2026 | 0 | 9 |
| Feb 2026 | 0 | 24 |
| Mar 2026 | 0 | 1 |
| Apr 2026 | 0 | 5 |
| May 2026 | 0 | 12 |
| Jun 2026 | 0 | 1 |
| Jul 2026 | 0 | 5 |
| Aug 2026 | 0 | 16 |
| Sep 2026 | 0 | 2 |
| Oct 2026 | 0 | 8 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 03, 2019 Filed Jun 5, 2019 20:23 UTC |
RECUPERO ANTHONY JChief Commercial Officer
|
Exercise / conversionCommon Stock | 1,000 | $4.32 | $4,320.00 |
DisclosureSEC source: 0001562180-19-003339 · primarydocument.xml · nonDerivative · entry 1 RECUPERO ANTHONY J · CIK 0001210230 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,273 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 18,469 shares issuable on settlement of restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one shares of the Issuer's common stock. Read SEC document |
| May 28, 2019 Filed May 30, 2019 19:51 UTC |
FRANCIS LAURAChief Financial Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 3,968 | $0.00 Strike: $4.32 | $0.00 |
DisclosureSEC source: 0001562180-19-003176 · primarydocument.xml · derivative · entry 6 FRANCIS LAURA · CIK 0001218802 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 176,246 Underlying: Common Stock · 3,968 shares Expires 2025-05-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The shares subject to the option vest in equal monthly installments over four years commencing on May 26, 2015, subject to Reporting Person's continued service through each relevant vesting date. The shares subject to this option may be exercised prior to vesting, subject to Issuer's right to repurchase. Read SEC document |
| May 28, 2019 Filed May 30, 2019 19:51 UTC |
FRANCIS LAURAChief Financial Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 2,518 | $0.00 Strike: $4.32 | $0.00 |
DisclosureSEC source: 0001562180-19-003176 · primarydocument.xml · derivative · entry 5 FRANCIS LAURA · CIK 0001218802 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 180,214 Underlying: Common Stock · 2,518 shares Expires 2025-05-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 28, 2019 Filed May 30, 2019 19:51 UTC |
FRANCIS LAURAChief Financial Officer
|
SaleCommon Stock | 2,518 | $15.97 | $40,204.15 |
DisclosureSEC source: 0001562180-19-003176 · primarydocument.xml · nonDerivative · entry 4 FRANCIS LAURA · CIK 0001218802 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,524 F2 · kind: The sale reported on this Form 4 was effected pursuant to a 10b5-1 trading plan. F3 · price: The price reported in column 4 is a weighted-average price. The shares were sold in multiple transactions ranging from $15.70 to $16.17, inclusive. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F1 · balance_after: Includes 25,078 shares issuable on settlement of restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one shares of the Issuer's common stock. Read SEC document |
| May 28, 2019 Filed May 30, 2019 19:51 UTC |
FRANCIS LAURAChief Financial Officer
|
SaleCommon Stock | 3,968 | $15.97 | $63,355.87 |
DisclosureSEC source: 0001562180-19-003176 · primarydocument.xml · nonDerivative · entry 3 FRANCIS LAURA · CIK 0001218802 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,042 F2 · kind: The sale reported on this Form 4 was effected pursuant to a 10b5-1 trading plan. F3 · price: The price reported in column 4 is a weighted-average price. The shares were sold in multiple transactions ranging from $15.70 to $16.17, inclusive. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F1 · balance_after: Includes 25,078 shares issuable on settlement of restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one shares of the Issuer's common stock. Read SEC document |
| May 28, 2019 Filed May 30, 2019 19:51 UTC |
FRANCIS LAURAChief Financial Officer
|
Exercise / conversionCommon Stock | 3,968 | $4.32 | $17,141.76 |
DisclosureSEC source: 0001562180-19-003176 · primarydocument.xml · nonDerivative · entry 2 FRANCIS LAURA · CIK 0001218802 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,010 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 25,078 shares issuable on settlement of restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one shares of the Issuer's common stock. Read SEC document |
| May 28, 2019 Filed May 30, 2019 19:51 UTC |
FRANCIS LAURAChief Financial Officer
|
Exercise / conversionCommon Stock | 2,518 | $4.32 | $10,877.76 |
DisclosureSEC source: 0001562180-19-003176 · primarydocument.xml · nonDerivative · entry 1 FRANCIS LAURA · CIK 0001218802 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,042 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 25,078 shares issuable on settlement of restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one shares of the Issuer's common stock. Read SEC document |
| May 16, 2019 Filed May 17, 2019 19:48 UTC |
PISETSKY MICHAEL A.GC & Chief Compliance Officer
|
SaleCommon Stock | 2,000 | $15.96 | $31,919.00 |
DisclosureSEC source: 0001562180-19-002943 · primarydocument.xml · nonDerivative · entry 1 Pisetsky Michael A · CIK 0001754765 · GC & Chief Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,073 F1 · kind: The sale reported on this Form 4 was effected pursuant to a 10b5-1 trading plan. F2 · shares: Shares purchased pursuant to the SI-BONE, Inc. 2018 Employee Stock Purchase Plan on May 15, 2019. F3 · price: The price reported in column 4 is a weighted-average price. The shares were sold in multiple transactions ranging from $15.85 to $16.13, inclusive. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 · balance_after: Includes 10,687 shares issuable on settlement of restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one shares of the Issuer's common stock. Read SEC document |
| May 16, 2019 Filed May 17, 2019 19:48 UTC |
FRANCIS LAURAChief Financial Officer
|
SaleCommon Stock | 2,000 | $15.96 | $31,915.60 |
DisclosureSEC source: 0001562180-19-002942 · primarydocument.xml · nonDerivative · entry 1 FRANCIS LAURA · CIK 0001218802 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,524 F1 · kind: The sale reported on this Form 4 was effected pursuant to a 10b5-1 trading plan. F2 · shares: Shares purchased pursuant to the SI-BONE, Inc. 2018 Employee Stock Purchase Plan on May 15, 2019. F3 · price: The price reported in column 4 is a weighted-average price. The shares were sold in multiple transactions ranging from $15.87 to $16.13, inclusive. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 · balance_after: Includes 25,078 shares issuable on settlement of restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one shares of the Issuer's common stock. Read SEC document |
| May 15, 2019 Filed May 17, 2019 19:48 UTC |
Yerby Scott AChief Technology Officer
|
SaleCommon Stock | 10,133 | $16.05 | $162,674.17 |
DisclosureSEC source: 0001562180-19-002941 · primarydocument.xml · nonDerivative · entry 1 Yerby Scott A · CIK 0001754756 · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 185,187 F1 · kind: The sale reported on this Form 4 was effected pursuant to a 10b5-1 trading plan. F2 · price: The price reported in column 4 is a weighted-average price. The shares were sold in multiple transactions ranging from $15.60 to $16.39, inclusive. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: Shares held by The Yerby Family Trust Dated May 22, 2007 Read SEC document |
| May 08, 2019 Filed May 10, 2019 21:02 UTC |
RECUPERO ANTHONY JChief Commercial Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 400 | $0.00 Strike: $4.32 | $0.00 |
DisclosureSEC source: 0001562180-19-002771 · primarydocument.xml · derivative · entry 3 RECUPERO ANTHONY J · CIK 0001210230 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 123,190 Underlying: Common Stock · 400 shares Expires 2026-07-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The shares subject to the option vest as to 25% on the 12-month anniversary of vesting commencement date, and 1/36th of the balance of the shares vest each month thereafter, subject to Reporting Person's continued service through each relevant vesting date. Read SEC document |
| May 08, 2019 Filed May 10, 2019 21:02 UTC |
RECUPERO ANTHONY JChief Commercial Officer
|
SaleCommon Stock | 400 | $18.00 | $7,200.00 |
DisclosureSEC source: 0001562180-19-002771 · primarydocument.xml · nonDerivative · entry 2 RECUPERO ANTHONY J · CIK 0001210230 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,273 F2 · kind: The sale reported on this Form 4 was effected pursuant to a 10b5-1 trading plan. F1 · balance_after: Includes 18,469 shares issuable on settlement of restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one shares of the Issuer's common stock. Read SEC document |
| May 08, 2019 Filed May 10, 2019 21:02 UTC |
RECUPERO ANTHONY JChief Commercial Officer
|
Exercise / conversionCommon Stock | 400 | $4.32 | $1,728.00 |
DisclosureSEC source: 0001562180-19-002771 · primarydocument.xml · nonDerivative · entry 1 RECUPERO ANTHONY J · CIK 0001210230 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,673 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 18,469 shares issuable on settlement of restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one shares of the Issuer's common stock. Read SEC document |
| May 06, 2019 Filed May 6, 2019 22:09 UTC |
Yerby Scott AChief Technology Officer
|
SaleCommon Stock | 648 | $16.93 | $10,970.64 |
DisclosureSEC source: 0001562180-19-002641 · primarydocument.xml · nonDerivative · entry 2 Yerby Scott A · CIK 0001754756 · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 195,320 F1 · kind: The sale reported on this Form 4 was effected pursuant to a 10b5-1 trading plan. F2 · ownership.nature: Shares held by The Yerby Family Trust Dated May 22, 2007 Read SEC document |
| May 02, 2019 Filed May 6, 2019 22:09 UTC |
Yerby Scott AChief Technology Officer
|
SaleCommon Stock | 376 | $16.57 | $6,230.32 |
DisclosureSEC source: 0001562180-19-002641 · primarydocument.xml · nonDerivative · entry 1 Yerby Scott A · CIK 0001754756 · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 195,968 F1 · kind: The sale reported on this Form 4 was effected pursuant to a 10b5-1 trading plan. F2 · ownership.nature: Shares held by The Yerby Family Trust Dated May 22, 2007 Read SEC document |
| May 01, 2019 Filed May 3, 2019 21:45 UTC |
RECUPERO ANTHONY JChief Commercial Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 1,000 | $0.00 Strike: $4.32 | $0.00 |
DisclosureSEC source: 0001562180-19-002581 · primarydocument.xml · derivative · entry 3 RECUPERO ANTHONY J · CIK 0001210230 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 123,590 Underlying: Common Stock · 1,000 shares Expires 2026-07-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The shares subject to the option vest as to 25% on the 12-month anniversary of July 5, 2016, and 1/36th of the balance of the shares vest each month thereafter, subject to Reporting Person's continued service through each relevant vesting date. Read SEC document |
| May 01, 2019 Filed May 3, 2019 21:45 UTC |
RECUPERO ANTHONY JChief Commercial Officer
|
SaleCommon Stock | 1,000 | $16.88 | $16,881.00 |
DisclosureSEC source: 0001562180-19-002581 · primarydocument.xml · nonDerivative · entry 2 RECUPERO ANTHONY J · CIK 0001210230 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,273 F2 · kind: The sale reported on this Form 4 was effected pursuant to a 10b5-1 trading plan. F3 · price: The price reported in column 4 is a weighted-average price. The shares were sold in multiple transactions ranging from $16.79 to $17.01, inclusive. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F1 · balance_after: Includes 18,469 shares issuable on settlement of restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one shares of the Issuer's common stock. Read SEC document |
| May 01, 2019 Filed May 3, 2019 21:45 UTC |
RECUPERO ANTHONY JChief Commercial Officer
|
Exercise / conversionCommon Stock | 1,000 | $4.32 | $4,320.00 |
DisclosureSEC source: 0001562180-19-002581 · primarydocument.xml · nonDerivative · entry 1 RECUPERO ANTHONY J · CIK 0001210230 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,273 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 18,469 shares issuable on settlement of restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one shares of the Issuer's common stock. Read SEC document |
| April 26, 2019 Filed May 1, 2019 01:05 UTC |
FRANCIS LAURAChief Financial Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 3,968 | $0.00 Strike: $4.32 | $0.00 |
DisclosureSEC source: 0001209191-19-026689 · doc4.xml · derivative · entry 3 FRANCIS LAURA · CIK 0001218802 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 182,732 Underlying: Common Stock · 3,968 shares Expires 2025-05-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The shares subject to the option vest in equal monthly installments over four years commencing on May 26, 2015, subject to Reporting Person's continued service through each relevant vesting date. The shares subject to this option may be exercised prior to vesting, subject to Issuer's right to repurchase. Read SEC document |
| April 26, 2019 Filed May 1, 2019 01:05 UTC |
FRANCIS LAURAChief Financial Officer
|
Exercise / conversionCommon Stock | 3,968 | $4.32 | $17,141.76 |
DisclosureSEC source: 0001209191-19-026689 · doc4.xml · nonDerivative · entry 1 FRANCIS LAURA · CIK 0001218802 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,492 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 25,078 shares issuable on settlement of restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one shares of the Issuer's common stock. Read SEC document |
| April 15, 2019 Filed Apr 17, 2019 19:43 UTC |
Reckling W CarltonCMO and VP, Medical Affairs
|
SaleCommon Stock | 151 | $16.59 | $2,505.09 |
DisclosureSEC source: 0001209191-19-025165 · doc4.xml · nonDerivative · entry 1 Reckling W Carlton · CIK 0001755111 · CMO and VP, Medical Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,049 F1 · kind: The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale satisfies the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. F2 · balance_after: Reflects shares issuable on settlement of restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one shares of the Issuer's common stock. Read SEC document |
| April 15, 2019 Filed Apr 17, 2019 23:55 UTC |
Yerby Scott AChief Technology Officer
|
SaleCommon Stock | 10,133 | $16.95 | $171,711.79 |
DisclosureSEC source: 0001209191-19-025173 · doc4.xml · nonDerivative · entry 2 Yerby Scott A · CIK 0001754756 · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 196,344 F3 · kind: The sale reported on this Form 4 was effected pursuant to a 10b5-1 trading plan. F4 · price: The price reported in column 4 is a weighted-average price. The shares were sold in multiple transactions ranging from $16.55 to $17.40, inclusive. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F5 · ownership.nature: Shares held by The Yerby Family Trust Dated May 22, 2007. Read SEC document |
| April 15, 2019 Filed Apr 17, 2019 23:55 UTC |
Yerby Scott AChief Technology Officer
|
SaleCommon Stock | 216 | $16.59 | $3,583.44 |
DisclosureSEC source: 0001209191-19-025173 · doc4.xml · nonDerivative · entry 1 Yerby Scott A · CIK 0001754756 · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,984 F1 · kind: The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale satisfies the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. F2 · balance_after: Includes 9,562 shares issuable on settlement of restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one shares of the Issuer's common stock. Read SEC document |
| April 15, 2019 Filed Apr 17, 2019 23:45 UTC |
RECUPERO ANTHONY JChief Commercial Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 1,000 | $0.00 Strike: $4.32 | $0.00 |
DisclosureSEC source: 0001209191-19-025166 · doc4.xml · derivative · entry 4 RECUPERO ANTHONY J · CIK 0001210230 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 124,590 Underlying: Common Stock · 1,000 shares Expires 2026-07-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The shares subject to the option vest as to 25% on the 12-month anniversary of July 5, 2016, and 1/36th of the balance of the shares vest each month thereafter, subject to Reporting Person's continued service through each relevant vesting date. Read SEC document |
| April 15, 2019 Filed Apr 17, 2019 23:45 UTC |
RECUPERO ANTHONY JChief Commercial Officer
|
SaleCommon Stock | 427 | $16.55 | $7,064.93 |
DisclosureSEC source: 0001209191-19-025166 · doc4.xml · nonDerivative · entry 3 RECUPERO ANTHONY J · CIK 0001210230 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,273 F4 · kind: The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale satisfies the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. F5 · price: The price reported in column 4 is a weighted-average price. The shares were sold in multiple transactions ranging from $16.40 to $16.59, inclusive. F1 · balance_after: Includes 18,469 shares issuable on settlement of restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one shares of the Issuer's common stock. Read SEC document |
| April 15, 2019 Filed Apr 17, 2019 23:45 UTC |
RECUPERO ANTHONY JChief Commercial Officer
|
SaleCommon Stock | 1,000 | $17.02 | $17,023.70 |
DisclosureSEC source: 0001209191-19-025166 · doc4.xml · nonDerivative · entry 2 RECUPERO ANTHONY J · CIK 0001210230 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,700 F2 · kind: The sale reported on this Form 4 was effected pursuant to a 10b5-1 trading plan. F3 · price: The price reported in column 4 is a weighted-average price. The shares were sold in multiple transactions ranging from $16.69 to $17.45, inclusive. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnotes 3 and 5. F1 · balance_after: Includes 18,469 shares issuable on settlement of restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one shares of the Issuer's common stock. Read SEC document |
| April 15, 2019 Filed Apr 17, 2019 23:45 UTC |
RECUPERO ANTHONY JChief Commercial Officer
|
Exercise / conversionCommon Stock | 1,000 | $4.32 | $4,320.00 |
DisclosureSEC source: 0001209191-19-025166 · doc4.xml · nonDerivative · entry 1 RECUPERO ANTHONY J · CIK 0001210230 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,700 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 18,469 shares issuable on settlement of restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one shares of the Issuer's common stock. Read SEC document |
| April 15, 2019 Filed Apr 17, 2019 23:40 UTC |
FRANCIS LAURAChief Financial Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 2,518 | $0.00 Strike: $4.32 | $0.00 |
DisclosureSEC source: 0001209191-19-025163 · doc4.xml · derivative · entry 4 FRANCIS LAURA · CIK 0001218802 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 186,700 Underlying: Common Stock · 2,518 shares Expires 2025-05-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The shares subject to the option vest in equal monthly installments over four years commencing on May 26, 2015, subject to Reporting Person's continued service through each relevant vesting date. The shares subject to this option may be exercised prior to vesting, subject to Issuer's right to repurchase. Read SEC document |
| April 15, 2019 Filed Apr 17, 2019 23:40 UTC |
FRANCIS LAURAChief Financial Officer
|
Exercise / conversionCommon Stock | 2,518 | $4.32 | $10,877.76 |
DisclosureSEC source: 0001209191-19-025163 · doc4.xml · nonDerivative · entry 1 FRANCIS LAURA · CIK 0001218802 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,536 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 25,078 shares issuable on settlement of restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one shares of the Issuer's common stock. Read SEC document |
| April 15, 2019 Filed Apr 17, 2019 23:46 UTC |
Reiley Mark ADirector
|
SaleCommon Stock | 10,000 | $16.95 | $169,459.00 |
DisclosureSEC source: 0001209191-19-025167 · doc4.xml · nonDerivative · entry 1 Reiley Mark A · CIK 0001754350 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 513,180 F1 · kind: The sale reported on this Form 4 was effected pursuant to a 10b5-1 trading plan. F2 · price: The price reported in column 4 is a weighted-average price. The shares were sold in multiple transactions ranging from $16.57 to $17.40, inclusive. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 15, 2019 Filed Apr 17, 2019 23:41 UTC |
PISETSKY MICHAEL A.GC & Chief Compliance Officer
|
SaleCommon Stock | 241 | $16.59 | $3,998.19 |
DisclosureSEC source: 0001209191-19-025164 · doc4.xml · nonDerivative · entry 1 Pisetsky Michael A · CIK 0001754765 · GC & Chief Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,073 F1 · kind: The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale satisfies the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. F2 · balance_after: Includes 10,687 shares issuable on settlement of restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one shares of the Issuer's common stock. Read SEC document |
| January 15, 2019 Filed Jan 17, 2019 23:42 UTC |
DUNN JEFFREY WDirector · Chairman, President & CEO
|
GrantStock Option (right to buy) · Derivative | 147,500 | $0.00 Strike: $22.00 | $0.00 |
DisclosureSEC source: 0001209191-19-004388 · doc4.xml · derivative · entry 3 DUNN JEFFREY W · CIK 0001035986 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 147,500 Underlying: Common Stock · 147,500 shares Expires 2029-01-15 F3 · derivative.exercise_date: The shares subject to the option vest in equal monthly installments over four years commencing on January 15, 2019, subject to the Reporting Person's continued service through each relevant vesting date. Read SEC document |
| January 15, 2019 Filed Jan 17, 2019 23:42 UTC |
DUNN JEFFREY WDirector · Chairman, President & CEO
|
GrantCommon Stock | 68,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-004388 · doc4.xml · nonDerivative · entry 1 DUNN JEFFREY W · CIK 0001035986 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,433 F1 · shares: Reflects shares issuable on settlement of restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one shares of the Issuer's common stock. The restricted stock unit will vest in equal quarterly installments over four years commencing on January 15, 2019, subject to the Reporting Person's continued service through each relevant vesting date. Read SEC document |
| January 15, 2019 Filed Jan 17, 2019 18:45 UTC |
Reckling W CarltonCMO and VP, Medical Affairs
|
GrantStock Option (right to purchase) · Derivative | 22,100 | $0.00 Strike: $22.00 | $0.00 |
DisclosureSEC source: 0001209191-19-004391 · doc4.xml · derivative · entry 2 Reckling W Carlton · CIK 0001755111 · CMO and VP, Medical Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,100 Underlying: Common Stock · 22,100 shares Expires 2029-01-15 F2 · derivative.exercise_date: The shares subject to the option vest in equal monthly installments over four years commencing on January 15, 2019, subject to Reporting Person's continued service through each relevant vesting date. Read SEC document |
| January 15, 2019 Filed Jan 17, 2019 18:45 UTC |
Reckling W CarltonCMO and VP, Medical Affairs
|
GrantCommon Stock | 10,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-004391 · doc4.xml · nonDerivative · entry 1 Reckling W Carlton · CIK 0001755111 · CMO and VP, Medical Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,200 F1 · shares: Reflects shares issuable on settlement of restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one shares of the Issuer's common stock. The shares subject to the restricted stock unit vest in equal quarterly installments over four years commencing on January 15, 2019, subject to the Reporting Person's continued service through each relevant vesting date. Read SEC document |
| January 15, 2019 Filed Jan 17, 2019 23:46 UTC |
Yerby Scott AChief Technology Officer
|
GrantStock Option (right to buy) · Derivative | 22,100 | $0.00 Strike: $22.00 | $0.00 |
DisclosureSEC source: 0001209191-19-004393 · doc4.xml · derivative · entry 3 Yerby Scott A · CIK 0001754756 · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,100 Underlying: Common Stock · 22,100 shares Expires 2029-01-15 F3 · derivative.exercise_date: The shares subject to the option vest in equal monthly installments over four years commencing on January 15, 2019, subject to Reporting Person's continued service through each relevant vesting date. Read SEC document |
| January 15, 2019 Filed Jan 17, 2019 23:46 UTC |
Yerby Scott AChief Technology Officer
|
GrantCommon Stock | 10,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-004393 · doc4.xml · nonDerivative · entry 1 Yerby Scott A · CIK 0001754756 · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,182 F1 · shares: Reflects shares issuable on settlement of restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one shares of the Issuer's common stock. The shares subject to the restricted stock unit vest in equal quarterly installments over four years commencing on January 15, 2019, subject to the Reporting Person's continued service through each relevant vesting date. Read SEC document |
| January 15, 2019 Filed Jan 17, 2019 23:47 UTC |
PISETSKY MICHAEL A.GC & Chief Compliance Officer
|
GrantStock Option (right to buy) · Derivative | 24,700 | $0.00 Strike: $22.00 | $0.00 |
DisclosureSEC source: 0001209191-19-004394 · doc4.xml · derivative · entry 2 Pisetsky Michael A · CIK 0001754765 · GC & Chief Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,700 Underlying: Common Stock · 24,700 shares Expires 2029-01-15 F2 · derivative.exercise_date: The shares subject to the option vest in equal monthly installments over four years commencing on January 15, 2019, subject to Reporting Person's continued service through each relevant vesting date. Read SEC document |
| January 15, 2019 Filed Jan 17, 2019 23:47 UTC |
PISETSKY MICHAEL A.GC & Chief Compliance Officer
|
GrantCommon Stock | 11,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-004394 · doc4.xml · nonDerivative · entry 1 Pisetsky Michael A · CIK 0001754765 · GC & Chief Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,314 F1 · shares: Reflects shares issuable on settlement of restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one shares of the Issuer's common stock. The shares subject to the restricted stock unit vest in equal quarterly installments over four years commencing on January 15, 2019, subject to the Reporting Person's continued service through each relevant vesting date. Read SEC document |
| January 15, 2019 Filed Jan 17, 2019 23:44 UTC |
RECUPERO ANTHONY JChief Commercial Officer
|
GrantStock Option (right to buy) · Derivative | 42,700 | $0.00 Strike: $22.00 | $0.00 |
DisclosureSEC source: 0001209191-19-004390 · doc4.xml · derivative · entry 2 RECUPERO ANTHONY J · CIK 0001210230 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,700 Underlying: Common Stock · 42,700 shares Expires 2029-01-15 F2 · derivative.exercise_date: The shares subject to the option vest in equal monthly installments over four years commencing on January 15, 2019, subject to Reporting Person's continued service through each relevant vesting date. Read SEC document |
| January 15, 2019 Filed Jan 17, 2019 23:44 UTC |
RECUPERO ANTHONY JChief Commercial Officer
|
GrantCommon Stock | 19,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-004390 · doc4.xml · nonDerivative · entry 1 RECUPERO ANTHONY J · CIK 0001210230 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,700 F1 · shares: Reflects shares issuable on settlement of restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one shares of the Issuer's common stock. The shares subject to the restricted stock unit vest in equal quarterly installments over four years commencing on January 15, 2019, subject to the Reporting Person's continued service through each relevant vesting date. Read SEC document |
| January 15, 2019 Filed Jan 17, 2019 23:43 UTC |
FRANCIS LAURAChief Financial Officer
|
GrantStock Option (right to buy) · Derivative | 49,400 | $0.00 Strike: $22.00 | $0.00 |
DisclosureSEC source: 0001209191-19-004389 · doc4.xml · derivative · entry 2 FRANCIS LAURA · CIK 0001218802 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,400 Underlying: Common Stock · 49,400 shares Expires 2029-01-15 F2 · derivative.exercise_date: The shares subject to the option vest in equal monthly installments over four years commencing on January 15, 2019, subject to Reporting Person's continued service through each relevant vesting date. Read SEC document |
| January 15, 2019 Filed Jan 17, 2019 23:43 UTC |
FRANCIS LAURAChief Financial Officer
|
GrantCommon Stock | 22,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-004389 · doc4.xml · nonDerivative · entry 1 FRANCIS LAURA · CIK 0001218802 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,018 F1 · shares: Reflects shares issuable on settlement of restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one shares of the Issuer's common stock. The shares subject to the restricted stock unit vest in equal quarterly installments over four years commencing on January 15, 2019, subject to the Reporting Person's continued service through each relevant vesting date. Read SEC document |
| October 19, 2018 Filed Oct 19, 2018 20:52 UTC |
ORBIMED ADVISORS LLCDirector
OrbiMed Capital GP V LLCDirector
|
ConversionSeries 7 Preferred Stock · Derivative | 179,404 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-055701 · doc4.xml · derivative · entry 5 ORBIMED ADVISORS LLC · CIK 0001055951 · Director OrbiMed Capital GP V LLC · CIK 0001615374 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By OrbiMed Private Investments V, LP Disclosed balance after: 0 Underlying: Common Stock · 179,404 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: The Issuer's Series 7 Preferred Stock automatically converted into an equal number of shares of Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date. F4 · price: The Issuer's Series 7 Preferred Stock automatically converted into an equal number of shares of Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date. F4 · derivative.exercise_date: The Issuer's Series 7 Preferred Stock automatically converted into an equal number of shares of Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date. F4 · derivative.expiration_date: The Issuer's Series 7 Preferred Stock automatically converted into an equal number of shares of Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date. F2 · ownership.nature: Shares held by OrbiMed Private Investments V, LP. ("OPI V"). OrbiMed Capital GP V LLC ("GP V") is the general partner of OPI V and OrbiMed Advisors LLC ("OrbiMed Advisors") is the managing member of GP V. By virtue of such relationships, GP V and OrbiMed Advisors may be deemed to have voting and investment power with respect to the shares held by OPI V and as a result may be deemed to have have beneficial ownership of such shares. OrbiMed Advisors exercises investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein. David P. Bonita, a member of the Issuer's board of directors, is an employee of OrbiMed Advisors. F3 · ownership.nature: This report on Form 4 is jointly filed by GP V and OrbiMed Advisors. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose. Read SEC document |
| October 19, 2018 Filed Oct 19, 2018 20:52 UTC |
ORBIMED ADVISORS LLCDirector
OrbiMed Capital GP V LLCDirector
|
ConversionSeries 6 Preferred Stock · Derivative | 572,326 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-055701 · doc4.xml · derivative · entry 4 ORBIMED ADVISORS LLC · CIK 0001055951 · Director OrbiMed Capital GP V LLC · CIK 0001615374 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By OrbiMed Private Investments V, LP Disclosed balance after: 0 Underlying: Common Stock · 605,964 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Issuer's Series 6 Preferred Stock automatically converted into approximately 1.05878 shares of Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date. F1 · price: The Issuer's Series 6 Preferred Stock automatically converted into approximately 1.05878 shares of Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date. F1 · derivative.exercise_date: The Issuer's Series 6 Preferred Stock automatically converted into approximately 1.05878 shares of Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date. F1 · derivative.expiration_date: The Issuer's Series 6 Preferred Stock automatically converted into approximately 1.05878 shares of Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date. F2 · ownership.nature: Shares held by OrbiMed Private Investments V, LP. ("OPI V"). OrbiMed Capital GP V LLC ("GP V") is the general partner of OPI V and OrbiMed Advisors LLC ("OrbiMed Advisors") is the managing member of GP V. By virtue of such relationships, GP V and OrbiMed Advisors may be deemed to have voting and investment power with respect to the shares held by OPI V and as a result may be deemed to have have beneficial ownership of such shares. OrbiMed Advisors exercises investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein. David P. Bonita, a member of the Issuer's board of directors, is an employee of OrbiMed Advisors. F3 · ownership.nature: This report on Form 4 is jointly filed by GP V and OrbiMed Advisors. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose. Read SEC document |
| October 19, 2018 Filed Oct 19, 2018 20:52 UTC |
ORBIMED ADVISORS LLCDirector
OrbiMed Capital GP V LLCDirector
|
PurchaseCommon Stock | 200,000 | $15.00 | $3,000,000.00 |
DisclosureSEC source: 0001209191-18-055701 · doc4.xml · nonDerivative · entry 3 ORBIMED ADVISORS LLC · CIK 0001055951 · Director OrbiMed Capital GP V LLC · CIK 0001615374 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By OrbiMed Private Investments V, LP Disclosed balance after: 985,368 F2 · ownership.nature: Shares held by OrbiMed Private Investments V, LP. ("OPI V"). OrbiMed Capital GP V LLC ("GP V") is the general partner of OPI V and OrbiMed Advisors LLC ("OrbiMed Advisors") is the managing member of GP V. By virtue of such relationships, GP V and OrbiMed Advisors may be deemed to have voting and investment power with respect to the shares held by OPI V and as a result may be deemed to have have beneficial ownership of such shares. OrbiMed Advisors exercises investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein. David P. Bonita, a member of the Issuer's board of directors, is an employee of OrbiMed Advisors. F3 · ownership.nature: This report on Form 4 is jointly filed by GP V and OrbiMed Advisors. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose. Read SEC document |
| October 19, 2018 Filed Oct 19, 2018 20:52 UTC |
ORBIMED ADVISORS LLCDirector
OrbiMed Capital GP V LLCDirector
|
ConversionCommon Stock | 179,404 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-055701 · doc4.xml · nonDerivative · entry 2 ORBIMED ADVISORS LLC · CIK 0001055951 · Director OrbiMed Capital GP V LLC · CIK 0001615374 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By OrbiMed Private Investments V, LP Disclosed balance after: 785,368 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · price: The Issuer's Series 7 Preferred Stock automatically converted into an equal number of shares of Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date. F2 · ownership.nature: Shares held by OrbiMed Private Investments V, LP. ("OPI V"). OrbiMed Capital GP V LLC ("GP V") is the general partner of OPI V and OrbiMed Advisors LLC ("OrbiMed Advisors") is the managing member of GP V. By virtue of such relationships, GP V and OrbiMed Advisors may be deemed to have voting and investment power with respect to the shares held by OPI V and as a result may be deemed to have have beneficial ownership of such shares. OrbiMed Advisors exercises investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein. David P. Bonita, a member of the Issuer's board of directors, is an employee of OrbiMed Advisors. F3 · ownership.nature: This report on Form 4 is jointly filed by GP V and OrbiMed Advisors. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose. Read SEC document |
| October 19, 2018 Filed Oct 19, 2018 20:52 UTC |
ORBIMED ADVISORS LLCDirector
OrbiMed Capital GP V LLCDirector
|
ConversionCommon Stock | 605,964 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-055701 · doc4.xml · nonDerivative · entry 1 ORBIMED ADVISORS LLC · CIK 0001055951 · Director OrbiMed Capital GP V LLC · CIK 0001615374 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By OrbiMed Private Investments V, LP Disclosed balance after: 605,964 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Issuer's Series 6 Preferred Stock automatically converted into approximately 1.05878 shares of Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date. F2 · ownership.nature: Shares held by OrbiMed Private Investments V, LP. ("OPI V"). OrbiMed Capital GP V LLC ("GP V") is the general partner of OPI V and OrbiMed Advisors LLC ("OrbiMed Advisors") is the managing member of GP V. By virtue of such relationships, GP V and OrbiMed Advisors may be deemed to have voting and investment power with respect to the shares held by OPI V and as a result may be deemed to have have beneficial ownership of such shares. OrbiMed Advisors exercises investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein. David P. Bonita, a member of the Issuer's board of directors, is an employee of OrbiMed Advisors. F3 · ownership.nature: This report on Form 4 is jointly filed by GP V and OrbiMed Advisors. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose. Read SEC document |
| October 19, 2018 Filed Oct 19, 2018 20:56 UTC |
Davis Timothy E JRDirector
|
ConversionSeries 6 Preferred Stock · Derivative | 6,070 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-055702 · doc4.xml · derivative · entry 2 Davis Timothy E JR · CIK 0001492082 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,426 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Issuer's Series 6 Preferred Stock automatically converted into approximately 1.05878 shares of Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date. F1 · price: The Issuer's Series 6 Preferred Stock automatically converted into approximately 1.05878 shares of Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date. F1 · derivative.exercise_date: The Issuer's Series 6 Preferred Stock automatically converted into approximately 1.05878 shares of Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date. F1 · derivative.expiration_date: The Issuer's Series 6 Preferred Stock automatically converted into approximately 1.05878 shares of Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date. Read SEC document |
| October 19, 2018 Filed Oct 19, 2018 20:56 UTC |
Davis Timothy E JRDirector
|
ConversionCommon Stock | 6,426 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-055702 · doc4.xml · nonDerivative · entry 1 Davis Timothy E JR · CIK 0001492082 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,426 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Issuer's Series 6 Preferred Stock automatically converted into approximately 1.05878 shares of Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.